Dihexa: Clinical Guide for Prescribing Practices
Dihexa is a synthetic peptide derived from angiotensin IV that activates the hepatocyte growth factor (HGF)/MET receptor pathway in the brain. Preclinical research has shown potent effects on synaptogenesis and cognitive function, with activity reported at picomolar concentrations. Clinical evidence is extremely limited.
Also Known As
How Dihexa Works
Dihexa binds to and activates hepatocyte growth factor (HGF), facilitating its dimerization and subsequent activation of the MET receptor tyrosine kinase in hippocampal and cortical neurons [1]. This triggers downstream PI3K/Akt and Ras/MAPK cascades that promote dendritic spine formation and synaptogenesis [3]. Dihexa demonstrates picomolar potency, making it approximately 10 million times more potent than BDNF in driving new synaptic connections in preclinical models [2].
Clinical Evidence
Harding et al. (2013) at Washington State University demonstrated that Dihexa facilitates HGF dimerization and MET receptor activation at picomolar concentrations [1]. McCoy et al. showed the peptide rescues scopolamine-induced cognitive deficits in rats and restores cognitive function in aged animals at doses as low as 2 pmol/kg [2]. Benoist et al. demonstrated efficacy in a dementia model via c-Met activation in the hippocampus, with treated animals performing comparably to young controls on cognitive tasks [3]. No human clinical trials have been published, and all evidence remains preclinical.
Clinical Uses
Patient Selection and Screening
Candidates include patients with early cognitive decline, age-related memory impairment, or mild cognitive impairment (MCI) who have failed conventional interventions and accept the investigational nature of treatment [2]. Absolute contraindication in patients with any current or prior malignancy due to HGF/MET pathway's role in tumor growth and metastasis [1]. Patients must undergo full cancer screening prior to initiation. Not appropriate for patients unwilling to accept the significant uncertainty in human safety and efficacy data [3].
Dosing and Administration
Subcutaneous injection dosing typically ranges from 10 to 20 mg administered once daily or every other day, with treatment courses of 4 to 8 weeks [2]. Topical (transdermal) cream formulations are applied to thin-skinned areas (inner wrist, behind ears) at concentrations of 5 to 20 mg per application. Due to the extreme potency at picomolar concentrations, dosing precision is paramount [1]. Shorter courses (4 weeks) with reassessment are prudent given the limited safety data [3]. Some clinicians use sublingual formulations as an alternative delivery route.
Route: Subcutaneous injection, topical (transdermal)
Protocol notes: Administered via subcutaneous injection or topical (transdermal cream). Dosing protocols are not standardized and based on limited clinical experience. Typical doses range from 10-20mg subcutaneously.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Dihexa occupies a premium niche for patients seeking cutting-edge cognitive interventions and willing to pay out-of-pocket for investigational treatments [1]. Its novel mechanism differentiates practices offering it from standard nootropic protocols [3]. However, the extensive informed consent requirements, cancer screening prerequisites, and liability considerations should be factored into service pricing and risk management.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Dihexa through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the evidence level for dihexa?
What are the theoretical risks of HGF/MET pathway activation?
References
- Harding JW et al. A small molecule that binds HGF/MET and facilitates dimerization activating the MET receptor. ACS Med Chem Lett. 2013;4(12):1228-32.
- McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-54.
- Benoist CC et al. Designed angiotensin IV analogs exhibit procognitive activity by activating c-Met in the hippocampus. J Pharmacol Exp Ther. 2014;351(1):35-44.
Related Peptides in Cognitive & Neurological
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Dihexa Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Dihexa Through Karpa